Brinke, Timo R. ten
Jergas, Hannah
Sisodia, Vibuthi
Barbe, Michael T.
Odekerken, Vincent J. J.
Verbaan, Dagmar
Dijk, Joke M.
Bot, Maarten
Beudel, Martijn
van den Munckhof, Pepijn
Schuurman, P. Rick
de Bie, Rob M. A.
Article History
Received: 28 June 2023
Accepted: 12 September 2023
First Online: 18 October 2023
Declarations
:
: The study will be conducted according to the principles of the Declaration of Helsinki (version of 2013) and in accordance with the Medical Research Involving Human Subjects Act (WMO) and other guidelines, regulations and Acts. Ethics approval was provided by the medical ethics committee (METC) of Amsterdam UMC, the Netherlands. Study monitoring will be performed in accordance with the ICH GCP guidelines. Written informed consent will be obtained from study participants.
: Not applicable.
: HJ reports personal fees from Boston scientific and has obtained funding from the Köln Fortune program. MTB received speakers honoraria from Medtronic, Boston Scientific, Abbott (formerly St. Jude), FomF, GE Medical, UCB, Bial, Apothekerverband Köln e.V., BDN, Esteve, and Ever. Research funding from the Felgenhauer-Stiftung, Forschungspool Klinische Studien (University of Cologne), Horizon 2020 (Gondola), Medtronic (ODIS, OPEL, BeAble), and Boston Scientific. He also received advisory honoraria for the IQWIG, Medtronic, Esteve and Abbvie. JMD received an unconditional supplementary grant from Medtronic for a randomized controlled trial comparing treatment with deep brain stimulation and continuous intrajejunal levodopa in advanced Parkinson’s disease (INVEST study). Martijn Beudel received funding from the Amsterdam UMC TKI-PPP grant (2021 & 2023 call), the EU Joint Programme – Neurodegenerative Disease Research (JPND) project (2021 call) and Stichting ParkinsonFonds (2022 call). RMAB received funding for research, paid to the institution, from Medtronic. PRS is consultant for Boston Scientific, Medtronic and Elekta on educational matters. The other authors have no competing interests.